- Report
- February 2025
- 200 Pages
Global
From €4089EUR$4,490USD£3,516GBP
- Report
- April 2025
- 250 Pages
Global
From €4089EUR$4,490USD£3,516GBP
- Report
- April 2025
- 250 Pages
Global
From €4089EUR$4,490USD£3,516GBP
- Report
- April 2025
- 200 Pages
Global
From €4089EUR$4,490USD£3,516GBP
- Report
- August 2024
- 200 Pages
Global
From €4507EUR$4,949USD£3,876GBP
- Report
- May 2021
- 266 Pages
Global
From €4508EUR$4,950USD£3,877GBP
- Report
- April 2024
- 180 Pages
Global
From €4098EUR$4,500USD£3,524GBP
- Report
- October 2023
- 170 Pages
Global
From €4098EUR$4,500USD£3,524GBP
- Report
- April 2023
- 150 Pages
Global
From €4326EUR$4,750USD£3,720GBP
- Report
- January 2024
- 160 Pages
Global
From €4098EUR$4,500USD£3,524GBP
- Report
- May 2022
- 242 Pages
Global
From €4052EUR$4,450USD£3,485GBP
- Report
- February 2024
- 108 Pages
Global
From €3500EUR$4,117USD£3,115GBP
Restriction endonucleases are enzymes that cleave DNA at specific sites. They are used in a variety of molecular biology techniques, such as cloning, sequencing, and gene expression analysis. Restriction endonucleases are classified according to their recognition sequence, cleavage site, and the type of DNA they cleave. The market for restriction endonucleases is driven by the increasing demand for molecular biology techniques in research and clinical applications.
The market for restriction endonucleases is highly competitive, with a number of companies offering a wide range of products. Prominent players in the market include New England Biolabs, Thermo Fisher Scientific, Promega Corporation, Agilent Technologies, Merck KGaA, Takara Bio, and Roche. Show Less Read more